Table 2. Comparison of patients with and without improvement in endocrine dysfunction post-endotherapy.

CBD, common bile duct; Hba1C, glycosylated hemoglobin; MPD, main pancreatic duct

n = 60	Improvement (n = 15)	No improvement (n = 45)	p-value
Age (mean ± SD) years	43.2 ±14.3	46.2 ± 12.3	0.14
Male, n (%)	12 (80%)	30 (66.6%)	0.651
Etiology: idiopathic alcoholic	11 (73.3%); 4 (26.6%)	10 (22.2%); 29 (64.4%)	0.004
MPD diameter (mean ± SD) mm	6.24 ±1.17	5.14 ± 1.6	0.051
Intraductal calculi, n (%)	6 (40%)	19 (42.2%)	0.416
Dominant stricture, n (%)	4 (26.6%)	12 (26.6%)	0.545
CBD stricture, n (%)	1 (6.6%)	2 (4.4%)	0.384
Pseudocyst, n (%)	1 (6.6%)	2 (4.4%)	0.756
Steatorrhea, n (%) (prior to endotherapy)	2 (13.3%)	24 (53.3%)	0.007
HbA1c (post-endotherapy) g/dl	6.38 ± 1.64	8.07 ± 1.84	<0.001